Luca Crippa will lead the new global commercial organisation of the IBSA Group: indeed, starting from January 1, 2023, he will assume the role of Chief Commercial Officer, reporting to Arturo Licenziati, President and CEO of the Group.
“I am honored, and I welcome this new challenge with great enthusiasm and humility”, commented Luca Crippa. “My goal will be to promote a consistent implementation of the Group’s strategy in all subsidiaries worldwide. It’s a challenging project for the company’s future, in which everyone will play a leading role”.
An appointment that comes after many years of experience in the pharmaceutical sector. Indeed, Luca Crippa has a solid scientific background, consolidated over the course of his career: after graduating in Chemistry from the University of Milan, he took the first steps of his professional path working as a genetic engineering scientist at the Istituto Mario Negri and as a medicinal chemist at GlaxoSmithKline.
He also completed his managerial training by studying Business Administration at SDA Bocconi, at INSEAD and at the London Business School.
Crippa has worked at international level, holding top positions in several corporations: in Bayer he was Head of Global Cardio Aspirin Business and Country Manager Croatia & Serbia; in 2012 he moved to Nestlé Health Science, with the role of Country Manager for Italy and Malta, to then become Vice President Global Consumer Care Healthy Aging Business and VP Global e-Business.
In 2018 he joined IBSA Farmaceutici as CEO and Managing Director, a position that he will continue to hold ad interim for the time necessary to ensure the transition of responsibilities to a new Chief Executive Officer.